Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
Cash Flow Statements
11 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Cash Flow (OCF) | -1.00 | -4.00 | -7.00 | -21.00 | -26.00 | -30.00 | -46.00 | -78.00 | -108.00 | -116.00 | -145.00 | |
| Operating Cash (Net) | -1.00 | -4.00 | -7.00 | -21.00 | -26.00 | -30.00 | -46.00 | -78.00 | -108.00 | -116.00 | -145.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | - - | - - | - - | - - | -37.00 | -57.00 | |
| Accounts Payable | - - | - - | 1.00 | 2.00 | - - | - - | 7.00 | 2.00 | - - | 25.00 | 2.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | - - | - - | - - | 3.00 | - - | 1.00 | 15.00 | - - | - - | 23.00 | -28.00 | |
| Other WC | - - | - - | - - | 1.00 | - - | 1.00 | 7.00 | -2.00 | - - | 41.00 | 34.00 | |
| Investing Activities | ||||||||||||
| Used Cash (Net) | - - | - - | - - | - - | - - | - - | - - | - - | - - | -53.00 | - - | |
| Capital Expenditure | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Purchases of Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Sale/Maturity of Investment | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Property, Plant, Equipment (P&PE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Acquisitions (Net) | - - | - - | - - | - - | - - | - - | - - | - - | - - | -53.00 | - - | |
| Other Investing Activities | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Financing Activities | ||||||||||||
| Used Cash (Net) | -3.00 | -5.00 | -52.00 | -9.00 | -23.00 | -10.00 | -252.00 | -42.00 | -11.00 | -284.00 | -331.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | -3.00 | -7.00 | -21.00 | - - | -44.00 | -83.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | - - | - - | 7 | 237 | 257 | |
| Issued | - - | - - | 45.00 | - - | 23.00 | 12.00 | 238.00 | 14.00 | 7.00 | 236.00 | 255.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | |
| Other Financing Activities | 3.00 | 5.00 | 7.00 | 9.00 | - - | - - | 21.00 | 49.00 | 4.00 | 136.00 | 159.00 | |
| Cash Balances | ||||||||||||
| Begin of Period | - - | 2.00 | 2.00 | 48.00 | 36.00 | 34.00 | 13.00 | 219.00 | 183.00 | 86.00 | 200.00 | |
| End of Period | 2.00 | 2.00 | 48.00 | 36.00 | 34.00 | 13.00 | 219.00 | 183.00 | 86.00 | 200.00 | 386.00 | |
| Change | 2.00 | - - | 45.00 | -11.00 | -2.00 | -20.00 | 205.00 | -36.00 | -97.00 | 114.00 | 185.00 | |
| Non-Cash Balances | ||||||||||||
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | 1.00 | 5.00 | 6.00 | |
| Stock Based Compensation | - - | - - | - - | 2.00 | 2.00 | - - | 6.00 | 14.00 | 20.00 | 37.00 | 62.00 | |
| Other | - - | - - | - - | - - | - - | - - | - - | 7.00 | - - | 3.00 | -10.00 | |
| Highlighted metrics | ||||||||||||
| Free Cash Flow (FCF) | -1.00 | -4.00 | -7.00 | -21.00 | -26.00 | -30.00 | -46.00 | -78.00 | -108.00 | -117.00 | -145.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | - - | - - | - - | - - | - - | -2,132.00 | -155.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - |